SCHEMBL14825401

SCHEMBL14825401

CCSCc1ccc2c(c1)c1c3c(c4c5cc(C)ccc5n5c4c1n2C1C[C@H](NC)[C@@H](CO)C5(C)O1)CNC3=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 11/20 0.60
MAP3K9 P80192 10/20 0.60
MAP3K10 Q02779 7/20 0.60
KDR P35968 4/20 0.60
FLT1 P17948 3/20 0.60
FLT4 P35916 3/20 0.60
DLK1 P80370 1/20 0.60
PAK3 O75914 2/20 0.59
NTRK1 P04629 3/20 0.57
PRKCQ Q04759 5/20 0.56
PRKD3 O94806 3/20 0.56
PRKCG P05129 3/20 0.56
PRKCZ Q05513 3/20 0.56
PRKCA P17252 3/20 0.56
PKN1 Q16512 2/20 0.56
PRKCB P05771 2/20 0.56
PRKCH P24723 2/20 0.56
PRKCI P41743 2/20 0.56
PRKCE Q02156 2/20 0.56
PRKCD Q05655 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825413 0.92 PAK3 (0.68) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL16437780 0.83 PRKCQ (0.76) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL1649555 0.80 MAP3K11 (0.67) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL13140134 0.79 MAP3K11 (0.93) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL13142263 0.79 MAP3K11 (0.93) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL5964631 0.76 MAP3K11 (0.86) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL8280372 0.76 MAP3K11 (0.79) MAP3K11MAP3K9MAP3K10KDRFLT1
Cep-1347 SCHEMBL8263437 0.75 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1
Cep-1347 SCHEMBL30198505 0.75 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1
Cep-1347 SCHEMBL29381680 0.75 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8771682-B2 Methods and compositions for reducing interleukin-4 or interleukin-13 signaling Technische Universtität Dresden (DE) 2014-07-08 US disclosed
US-20130084275-A1 Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling TECHNISCHE UNIVERSITAT DRESDEN (DE) 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130084275-A1 Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling IL4, IL2RA, STAT6 MAP3K11 185/4885MAP3K9 293/4885MAP3K10 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.